PLCG1 (Phospho-Tyr771) Colorimetric Cell-Based ELISA Kit

CAT:
519-EKC1993
Size:
1 Kit, Containing two 96 Well Plates and all necessary reagents
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
PLCG1 (Phospho-Tyr771) Colorimetric Cell-Based ELISA Kit - image 1

PLCG1 (Phospho-Tyr771) Colorimetric Cell-Based ELISA Kit

  • Description:

    The PLCG1 (Phospho-Tyr771) Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor PLCG1 (Phospho-Tyr771) protein expression profile in cells. The kit can be used for measuring the relative amounts of PLCG1 (Phospho-Tyr771) in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on PLCG1 (Phospho-Tyr771) .
  • Synonyms:

    1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1; PLC-148; Phosphoinositide phospholipase C-gamma-1; Phospholipase C-II; PLC-II; Phospholipase C-gamma-1; PLC-gamma-1; PLCG1; PLC1
  • Gene Name:

    PLCG1
  • UniProt:

    P19174
  • Reactivity:

    Human, Mouse, Rat
  • Applications:

    ELISA
  • Sample Type:

    Cell lines
  • Detection Range:

    > 5000 cells/well
  • Function:

    Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) . Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand- mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganization and cell migration.
  • Molecular Weight:

    148532 MW
  • Shipping Conditions:

    Available
  • Storage Conditions:

    Store at 4°C for up to 6 months.
  • Other Gene Names:

    1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1
  • Subcellular Location:

    Cell projection, lamellipodium. Cell projection, ruffle. Rapidly redistributed to ruffles and lamellipodia structures in response to epidermal growth factor (EGF) treatment.